Increased risk of urothelial cancer in young and middle aged patients with end-stage renal disease

Journal of the Formosan Medical Association

Volumn 114, Issue 1, 2015, Pages 52-57

  Wang, Shuo Meng ^a,b   Lai, Ming Nan ^c   Chen, Pau Chung ^b   Wang, Jung Der ^d,e  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FENG CHIA UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

End stage renal disease; Standardized incidence ratio; Upper tract urothelial cancer; Urothelial cancer

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; END STAGE RENAL DISEASE; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PELVIS CANCER; STANDARDIZED INCIDENCE RATIO; TAIWAN; UPPER TRACT UROTHELIAL CANCER; URETER CANCER; URINARY TRACT CANCER; UROTHELIAL CANCER; YOUNG ADULT; COMPLICATION; INCIDENCE; KIDNEY FAILURE, CHRONIC; RISK FACTOR; UROLOGIC NEOPLASMS;

ADULT; AGED; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS; TAIWAN; UROLOGIC NEOPLASMS;

EID: 84921434143     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.10.022     Document Type: Article

References (34)

1. Maisonneueve P., Agodoa L., Gellert R., Stewart J.H., Buccianti G., Lowenfels A.B., et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999, 354:93-99.
2. Stewart J.H., Buccianti G., Agodoa L., Gellert R., McCredie M.R., Lowenfels A.B., et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, Australia and New Zealand. J Am Soc Nephrol 2003, 14:197-207.
3. Akiyama T., Imanishi M., Matsuda H., Nishioka T., Kunikata S., Kurita T. Difference amongst races in post-transplant malignancies: report from an oriental country. Transplant Proc 1998, 30:2058-2059.
4. Agraharkar M.L., Cinclair R.D., Kuo Y.F., Daller J.A., Shahnian V.B. Risk of malignancy with long-term immuno-suppression in renal transplant recipients. Kidney Int 2004, 66:383-389.
5. Chuang C.H., Lee C.T., Tsai T.L., Chen J.B., Hsu K.T., Hsieh H.H. Urological malignancy in chronic dialysis patients. Acta Nephrologica 2002, 16:19-24.
6. Chang C.H., Yang C.M., Yang A.H. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 2007, 109:1487-1492.
7. Ou J.H., Pan C.C., Lin S.N., Tzai T.S., Yang W.H., Chang C.C., et al. Transitional cell carcinoma in dialysis patients. Eur Urol 2000, 37:90-94.
8. Chen K.S., Lai M.K., Huang C.C., Chu S.H., Leu M.L. Urologic cancers in uremic patients. Am J Kidney Dis 1995, 25:694-700.
9. Tan H.F., Chang C.K., Tseng H.F., Lin W. Evaluation of the national notifiable disease surveillance system in Taiwan: an example of varicella reporting. Vaccine 2007, 25:2630-2633.
10. Chen C.J., Wu M.M., Lee S.S., Wang J.D., Cheng S.H., Wu H.Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988, 8:452-460.
11. Chen C.J., Chuang Y.C., Lin T.M., Wu H.Y. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 1985, 45:5895-5899.
12. Wen C.P., Tsai S.P., Chung W.S.I. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008, 148:258-267.
13. Jiaan B.P., Yu C.C., Lee Y.H., Huang J.K. Uraemia with concomitant urothelial cancer. Br J Urol 1993, 72:458-461.
14. Boon N.A., Michael J. Multiple neoplasia in a patient on dialysis presenting with haematuria. Br J Urol 1984, 56:96-97.
15. Tsai H.J., Hsieh H.H. Adult polycystic kidneys associated with transitional cell carcinoma: A case report. Chang Keng I Hsueh Tsa Chih 1987, 10:257-262.
16. Fraley E.E. Cancer of the renal pelvis. Genitourinary cancer 1978, 134. WB Saunders, Philadelphia. D.G. Skinner, J.B. deKernion (Eds.).
17. Chou Y.H., Huang C.H. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999, 85:1342-1344.
18. Matas A.J., Simmons R.L., Kjellstrand C.M., Buselmeier T.J., Najarian J.S. Increased incidence of malignancy during chronic renal failure. Lancet 1975, 1:883-886.
19. Port F.K., Ragheb N.E., Schwartz A.G., Hawthorne V.M. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989, 14:119-123.
20. Kjellstrand C.M. Are malignancies increased in uremia?. Nephron 1979, 23:159-161.
21. Yang W.C., Hwang S.J. Taiwan Society of Nephrology. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 2008, 23:3977-3982.
22. Wu C.F., Pang S.T., Shee J.J., Chang P.L., Chuang C.K., Chen C.S., et al. Identification of genetic alterations in upper urinary tract urothelial carcinoma in end-stage renal disease patients. Genes Chromosomes Cancer 2010, 49:928-934.
23. Hsieh Y.F., Ling G.C., Lu Y.B., Yeh M.T., Chiang C.P. Incidence of tumor of the renal pelvis in Taiwan. J Formos Med Assoc 1979, 78:749-753.
24. Wu M.M., Kuo T.L., Hwang Y.H., Chen C.J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular disease. Am J Epidemiol 1989, 130:1123-1132.
25. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans; Suppl 7. Overall evaluations of carcinogenicity: updating of IARC monographs volumes 1-42 1987, 29-33. Arsenic and arsenic compounds, World Health Organization, International Agency for Research on Cancer, Lyon: France.
26. Lai M.N., Wang S.M., Chen P.C., Chen Y.Y., Wang J.D. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010, 102:179-186.
27. Chen C.H., Shun C.T., Huang K.H., Huang C.Y., Yu H.J., Pu Y.S. Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease. Urology 2008, 71:1155-1160.
28. Vanherweghem J.L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341:387-391.
29. Cukovic C., Djukanovic L., Jankovic S., Stanojcić A., Dragićević P., Radmilović A., et al. Malignant tumor in hemodialysis patients. Nephron 1996, 73:710-712.
30. Arlt V.M., Stiborova M., Simoes M.L., Simões M.L., Lord G.M., Nortier J.L., et al. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 2007, 28:2253-2261.
31. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. PNAS 2007, 104:12129-12134.
32. Lai M.N., Lai J.N., Chen P.C., Tseng W.L., Chen Y.Y., Hwang J.S., et al. Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. Nephrology (Carlton) 2009, 14:227-234.
33. Lai M.N., Lai J.N., Chen P.C., Hsieh S.C., Hu F.C. Wang JD. Risks of kidney failure associated with consumption of herbal products containing mu tong or fangchi: a population-based case-control study. Am J Kidney Dis 2010, 55:507-518.
34. Arlt V.M., Stiborova M., Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002, 17:265-277.